Stock Events

Stock Events

Atea Pharmaceuticals 

$5.83
31
+$0.01+0.17% Friday 20:00
+$0.02+0.34%Friday 22:48After hours

Statistics

Day High
5.85
Day Low
5.83
52W High
6.45
52W Low
2.78
Volume
10,574
Avg. Volume
-
Mkt Cap
467.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.48
-0.38
-0.29
Expected EPS
-0.505
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-158.35MNet Income

Analyst Ratings

8.50Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVIR. It's not an investment recommendation.
Apple
7
AAPL
Microsoft
6
MSFT
Amazon
6
AMZN
Johnson & Johnson
6
JNJ

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a leading biopharmaceutical company that competes with Atea Pharmaceuticals in the development of antiviral drugs, including treatments for COVID-19, HIV, and hepatitis.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that competes in the antiviral space, particularly with its development of treatments for diseases like COVID-19, making it a direct competitor to Atea Pharmaceuticals.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company that competes with Atea Pharmaceuticals in the development of antiviral drugs, including COVID-19 treatments, through its extensive research and development capabilities.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories competes with Atea Pharmaceuticals through its development of diagnostics and treatments for infectious diseases, including viruses, leveraging its broad healthcare portfolio.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of treatments for infectious diseases, including COVID-19, positioning it as a competitor to Atea Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes with Atea Pharmaceuticals in the area of infectious diseases, focusing on the development of antiviral drugs and treatments for various conditions, including HIV.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its development of antibody treatments for diseases like COVID-19, directly competing with Atea Pharmaceuticals in the antiviral treatment space.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals competes with Atea Pharmaceuticals in the development of treatments for viral diseases, focusing on innovative therapies for cystic fibrosis and other serious diseases.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline is a global healthcare company that competes with Atea Pharmaceuticals in the development of vaccines and treatments for infectious diseases, including antiviral drugs.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that competes with Atea Pharmaceuticals in the development of vaccines and treatments for various infectious diseases, including COVID-19.

About

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Show more...
CEO
Jean-Pierre Sommadossi
Employees
55
Country
United States
ISIN
US04683R1068

Listings

XNAS
US
AVIR
BOATS
BOATS
AVIR.BOATS

0 Comments

Share your thoughts

FAQ

What is Atea Pharmaceuticals stock price today?▼
The current price of AVIR is $5.83 USD — it has increased by +0.17% in the past 24 hours. Watch Atea Pharmaceuticals stock price performance more closely on the chart.
What is Atea Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Atea Pharmaceuticals stocks are traded under the ticker AVIR.
Is Atea Pharmaceuticals stock price growing?▼
AVIR stock has risen by +8.77% compared to the previous week, the month change is a +22.74% rise, over the last year Atea Pharmaceuticals has showed a +73% increase.
What is Atea Pharmaceuticals market cap?▼
Today Atea Pharmaceuticals has the market capitalization of 467.59M
When is the next Atea Pharmaceuticals earnings date?▼
Atea Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Atea Pharmaceuticals earnings last quarter?▼
AVIR earnings for the last quarter are -0.41 USD per share, whereas the estimation was -0.56 USD resulting in a +26.13% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atea Pharmaceuticals revenue for the last year?▼
Atea Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Atea Pharmaceuticals net income for the last year?▼
AVIR net income for the last year is -158.35M USD.
How many employees does Atea Pharmaceuticals have?▼
As of September 05, 2026, the company has 55 employees.
In which sector is Atea Pharmaceuticals located?▼
Atea Pharmaceuticals operates in the Health & Wellness sector.
When did Atea Pharmaceuticals complete a stock split?▼
The last stock split for Atea Pharmaceuticals was on February 14, 2018 with a ratio of 1:11.
Where is Atea Pharmaceuticals headquartered?▼
Atea Pharmaceuticals is headquartered in BOSTON, United States.